VAL201 is being developed to treat hormone-resistant prostate cancer and is currently undergoing a phase I/II study.
The latest feedback echoes that from an earlier cohort on a lower dose of the medication. ValiRx will now be allowed to increase the amount of VAL201 administered to cancer sufferers one last time to assess its impact.
“The company believes that being able to dose patients at levels and with a frequency that matches the pre-clinical validated amounts that are therapeutically relevant, represents another important milestone,” ValiRx said in a short stock exchange statement.
The firm will provide updates as the trial progresses. Eagerly awaited will be any hint of efficacy. Researchers saw “tumour modulating effects” pre-clinically and they have been “hinted at during the in-human stage”.